Pacira BioSciences stock: Viatris starts USD 36.50 tender offer

Published on 11/05/2026 at 03:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Pacira BioSciences stock is tied to Viatris' all-cash takeover bid. Shareholders can tender until November 16 unless the offer is extended.

Deal timetable and portfolio focus

Viatris has launched the tender offer as the next step in its planned acquisition of Pacira.
Pacira's board unanimously recommends that shareholders accept the offer.
Pacira's non-opioid pain portfolio includes two commercial-stage treatments and a gene therapy asset.

PCRX, US6951271005, Illustration mit AI erstellt.

Viatris announced on October 30, 2026, that its wholly owned subsidiary had commenced a tender offer for all outstanding Pacira BioSciences shares. The offer is part of the planned acquisition of Pacira and was reported by BioSpace on November 1.

Tender offer sets next deadline

The cash offer covers all issued and outstanding Pacira shares. The tender period is scheduled to expire one minute after 11:59 p.m. Eastern Time on November 16, unless Viatris extends or terminates the offer earlier.

After the tender offer, Viatris plans to merge its acquisition subsidiary into Pacira. Each remaining Pacira share would be converted into the right to receive the cash consideration, and the transaction would not require a separate shareholder vote under Section 251(h) of Delaware law.

Conditions shape completion

Viatris' payment obligation is subject to conditions including valid tenders representing at least one share more than 50 percent of Pacira's outstanding shares, the expiration or termination of the applicable antitrust waiting period and the absence of legal restraints. The offer is not subject to a financing condition.

Pacira's board has filed a Schedule 14D-9 with the U.S. Securities and Exchange Commission and unanimously recommends that shareholders tender their shares. The transaction therefore moves from the previously announced agreement into its formal tender period, while completion remains conditional on the offer requirements.

Pacira's non-opioid portfolio

Pacira develops non-opioid pain therapies and specializes in targeted, locally administered treatments. Its portfolio includes the commercial-stage products EXPAREL and ZILRETTA, while the company is also advancing a gene therapy asset aimed at prevalent diseases such as osteoarthritis. Pacira is headquartered in the United States and focuses on bringing non-opioid treatment options to patients.